Voriconazole Supply in 2026: A Provider Briefing

Voriconazole remains the cornerstone of therapy for invasive aspergillosis and several other serious mold infections. However, supply disruptions that began in earnest in 2019 have continued into 2026, creating real challenges for clinicians managing immunocompromised patients with life-threatening fungal disease.

This article summarizes the current supply picture, prescribing implications, available alternatives, and practical tools to help your patients maintain access to antifungal therapy.

Shortage Timeline

Voriconazole supply has been uneven for several years:

• 2019–2020: Initial reports of IV Voriconazole shortages as generic manufacturers experienced production disruptions. Oral formulations largely unaffected.
• 2021–2022: Intermittent spot shortages of both IV and oral formulations. ASHP and FDA shortage databases reflected ongoing supply issues from multiple manufacturers.
• 2023–2024: Shortage intensified, particularly for the IV injection. Manufacturing quality issues at key facilities (Teva, Aurobindo) contributed to extended backorders. Increased demand from rising invasive fungal infection rates — driven by expanded use of immunosuppressive biologics, CAR-T therapy, and solid organ transplant volumes — compounded the problem.
• 2025–2026: Gradual improvement in oral tablet supply as additional generic lots reached market. IV formulation remains inconsistently available. Oral suspension supply limited due to fewer manufacturers.

Prescribing Implications

The shortage has several direct implications for clinical practice:

Therapeutic Drug Monitoring (TDM)

With supply constraints, some patients may experience gaps in therapy or switch between formulations (e.g., IV to oral, tablets to suspension). TDM becomes even more critical in this context. Voriconazole exhibits significant pharmacokinetic variability influenced by CYP2C19 polymorphisms, hepatic function, drug interactions, and formulation. Target trough levels of 1–5.5 mcg/mL remain the standard, with levels above 5.5 mcg/mL associated with increased neurotoxicity risk.

Formulation Switching

When one formulation is unavailable, switching may be necessary:

• IV to oral: Bioavailability of oral Voriconazole is approximately 96%, making the switch straightforward in patients who can tolerate oral medication. Standard oral dosing applies.
• Tablets to suspension: The oral suspension (40 mg/mL) has comparable bioavailability to tablets. Note that it should be taken on an empty stomach and not mixed with other liquids.
• Oral to IV: The IV formulation uses sulfobutylether beta-cyclodextrin (SBECD) as a vehicle, which accumulates in patients with CrCl <50 mL/min. Use caution or avoid IV formulation in renal impairment.

Drug Interactions

Voriconazole's extensive CYP450 interaction profile (primarily CYP2C19, CYP3A4, and CYP2C9) remains a major consideration. Key interactions affecting your prescribing decisions:

• Immunosuppressants: Reduce tacrolimus by ~66% and cyclosporine by ~50% when initiating Voriconazole. Sirolimus is contraindicated.
• Anticonvulsants: Phenytoin, carbamazepine, and phenobarbital significantly reduce Voriconazole levels. Phenytoin requires bidirectional dose adjustments.
• Antiretrovirals: Efavirenz and ritonavir interactions require specific dose modifications.
• QT-prolonging agents: Avoid co-administration with drugs that prolong the QT interval.

A detailed interaction reference is available at Voriconazole Drug Interactions: What to Avoid.

Current Availability Picture

As of early 2026:

• Oral tablets (50 mg, 200 mg): Generally available through standard distribution channels, though spot shortages persist at individual pharmacies. Multiple generic manufacturers are supplying the market.
• Oral suspension (40 mg/mL): Limited availability. Fewer manufacturers produce this formulation. Consider compounding pharmacies as a backup.
• IV injection (200 mg vials): Intermittently available. Hospital pharmacies and specialty distributors may have more reliable access than retail chains. Consider the oral route when clinically appropriate to preserve IV supply for patients who cannot take oral medications.

Cost and Access Considerations

Even when Voriconazole is available, cost can be a barrier to adherence:

• Generic oral tablets: $300–$900/month cash price; $80–$250 with discount cards
• Brand Vfend: $2,000–$5,000+/month (rarely necessary given generic availability)
• Insurance: Most plans cover generic Voriconazole, though prior authorization may be required. Specialty pharmacy channels may offer better pricing and supply reliability.
• Patient assistance: Pfizer RxPathways (1-844-989-7284) for brand Vfend. NeedyMeds and RxAssist maintain directories of generic assistance programs.

For a patient-facing cost guide you can share: How to Save Money on Voriconazole.

Tools and Resources for Providers

Several tools can help you and your patients navigate the shortage:

• Medfinder for Providers — real-time pharmacy stock lookup. Direct patients here or use it during clinic visits to identify pharmacies with Voriconazole in stock.
• FDA Drug Shortage Database (accessdata.fda.gov) — official shortage status and estimated resolution dates.
• ASHP Drug Shortage Resource Center (ashp.org) — clinical guidance for managing therapy during shortages.
• IDSA Practice Guidelines — current recommendations for invasive aspergillosis treatment, including alternative agent guidance.

Alternative Agents

When Voriconazole is unavailable or not tolerated, consider:

• Isavuconazole (Cresemba): FDA-approved for invasive aspergillosis and mucormycosis. Non-inferior to Voriconazole in the SECURE trial. Fewer drug interactions, no visual disturbances, no QT prolongation. IV formulation does not contain SBECD (safe in renal impairment). Expensive — requires prior authorization from most payers.
• Posaconazole (Noxafil): Delayed-release tablets provide reliable oral bioavailability. Broad-spectrum coverage including mucormycosis. Well-established for prophylaxis in neutropenic patients. Consider for salvage therapy when first-line agents are unavailable.
• Liposomal Amphotericin B (AmBisome): IV only. Gold standard for mucormycosis and salvage therapy for aspergillosis. Nephrotoxicity remains the limiting factor. Reserve for patients who cannot receive or have failed azole therapy.
• Echinocandins (Caspofungin, Micafungin): Not recommended as monotherapy for invasive aspergillosis but may be used in combination with azoles for salvage therapy.

A patient-facing alternatives guide is available at Alternatives to Voriconazole.

Looking Ahead

The antifungal pipeline offers some hope for reducing dependence on Voriconazole:

• Olorofim — a novel dihydroorotate dehydrogenase (DHODH) inhibitor with activity against Aspergillus. May provide a non-azole oral option for invasive aspergillosis.
• Fosmanogepix — targets the Gwt1 enzyme involved in fungal cell wall anchoring. Broad-spectrum activity in development.
• Rezafungin — a long-acting echinocandin with once-weekly IV dosing. FDA-approved for candidemia; being studied for other indications.

Until these agents achieve broader availability, Voriconazole will remain a critical antifungal, and managing its supply disruptions will continue to require proactive clinical strategies.

Final Thoughts

The Voriconazole shortage is an ongoing challenge that demands clinical flexibility and proactive planning. Monitor the FDA and ASHP shortage databases, leverage tools like Medfinder for Providers, maintain familiarity with alternative agents, and ensure patients have access to cost-saving resources.

For a provider-focused guide on helping patients locate this medication, see How to Help Your Patients Find Voriconazole in Stock.